Literature DB >> 9266740

Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects.

C W Shults1, R H Haas, D Passov, M F Beal.   

Abstract

The activities of complex I and complex II/III in platelet mitochondria are reduced in patients with early, untreated Parkinson's disease. Coenzyme Q10 is the electron acceptor for complex I and complex II. We found that the level of coenzyme Q10 was significantly lower in mitochondria from parkinsonian patients than in mitochondria from age- and sex-matched control subjects and that the levels of coenzyme Q10 and the activities of complex I and complex II/III were significantly correlated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266740     DOI: 10.1002/ana.410420221

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  72 in total

Review 1.  Mitochondrial DNA analysis: polymorphisms and pathogenicity.

Authors:  P F Chinnery; N Howell; R M Andrews; D M Turnbull
Journal:  J Med Genet       Date:  1999-07       Impact factor: 6.318

2.  [Statin-induced Parkinson's-syndrome. Reader's letter on the article by J. Finsterer in "Der Nervenarzt" (2003) 74:115-122].

Authors:  Th Müller
Journal:  Nervenarzt       Date:  2003-05-10       Impact factor: 1.214

3.  Platelet mitochondrial complex I and I+III activities do not correlate with cerebral mitochondrial oxidative metabolism.

Authors:  William J Powers; Richard H Haas; Thuy Le; Tom O Videen; Joanne Markham; Joel S Perlmutter
Journal:  J Cereb Blood Flow Metab       Date:  2010-10-20       Impact factor: 6.200

4.  CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.

Authors:  David A Loeffler; Lynnae M Smith; Mary P Coffey; Jan O Aasly; Peter A LeWitt
Journal:  J Neural Transm (Vienna)       Date:  2015-11-03       Impact factor: 3.575

5.  Expression of Nrf2 in neurodegenerative diseases.

Authors:  Chenere P Ramsey; Charles A Glass; Marshall B Montgomery; Kathryn A Lindl; Gillian P Ritson; Luis A Chia; Ronald L Hamilton; Charleen T Chu; Kelly L Jordan-Sciutto
Journal:  J Neuropathol Exp Neurol       Date:  2007-01       Impact factor: 3.685

Review 6.  Neurodegeneration and neuroprotection in Parkinson disease.

Authors:  Stanley Fahn; David Sulzer
Journal:  NeuroRx       Date:  2004-01

7.  Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK.

Authors:  Claudia Becker; Susan S Jick; Christoph R Meier
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 8.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 9.  Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance.

Authors:  Chun Zhou; Yong Huang; Serge Przedborski
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 10.  Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease.

Authors:  D James Surmeier; Jaime N Guzman; Javier Sanchez-Padilla
Journal:  Cell Calcium       Date:  2010-01-06       Impact factor: 6.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.